Published in AJR Am J Roentgenol on February 01, 2006
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging (2014) 2.79
Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. Ann Oncol (2008) 1.15
Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer: comparison with PET and enhanced CT. Eur J Nucl Med Mol Imaging (2008) 1.12
Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT. Eur J Nucl Med Mol Imaging (2008) 1.09
Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT. Eur J Nucl Med Mol Imaging (2008) 1.02
Performance of integrated FDG PET/contrast-enhanced CT in the diagnosis of recurrent colorectal cancer: Comparison with integrated FDG PET/non-contrast-enhanced CT and enhanced CT. Eur J Nucl Med Mol Imaging (2009) 0.98
Accuracy and precision of radioactivity quantification in nuclear medicine images. Semin Nucl Med (2012) 0.96
Non-enhanced CT versus contrast-enhanced CT in integrated PET/CT studies for nodal staging of rectal cancer. Eur J Nucl Med Mol Imaging (2007) 0.96
Dosimetry of FDG PET/CT and other molecular imaging applications in pediatric patients. Pediatr Radiol (2008) 0.89
Effect of MR contrast agents on quantitative accuracy of PET in combined whole-body PET/MR imaging. Eur J Nucl Med Mol Imaging (2012) 0.88
Accuracy of CT-based attenuation correction in PET/CT bone imaging. Phys Med Biol (2012) 0.85
Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PET/CT studies for the diagnosis of uterine cancer recurrence. Eur J Nucl Med Mol Imaging (2010) 0.84
Multiphase contrast-enhanced CT with highly concentrated contrast agent can be used for PET attenuation correction in integrated PET/CT imaging. Eur J Nucl Med Mol Imaging (2011) 0.81
PET-specific parameters and radiotracers in theoretical tumour modelling. Comput Math Methods Med (2015) 0.80
PET/CT in lung cancer: Influence of contrast medium on quantitative and clinical assessment. Eur Radiol (2012) 0.80
Frequency and etiology of solitary hot spots in the pelvis at whole-body positron emission tomography/computed tomography imaging. Clin Imaging (2009) 0.79
Does chemotherapy influence the quantification of SUV when contrast-enhanced CT is used in PET/CT in lymphoma? Eur J Nucl Med Mol Imaging (2007) 0.78
Contrast-enhanced small-animal PET/CT in cancer research: strong improvement of diagnostic accuracy without significant alteration of quantitative accuracy and NEMA NU 4-2008 image quality parameters. EJNMMI Res (2013) 0.78
PET/CT imaging: what radiologists need to know. Cancer Imaging (2007) 0.75
Intravenous contrast-enhanced CT can be used for CT-based attenuation correction in clinical (111)In-octreotide SPECT/CT. EJNMMI Phys (2015) 0.75
Contrast medium injection protocol adjusted for body surface area in combined PET/CT. Eur Radiol (2013) 0.75
American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol (2005) 8.56
The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg (2012) 4.68
Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2014) 4.61
We should desist using RECIST, at least in GIST. J Clin Oncol (2007) 4.51
Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol (2003) 4.07
Bone imaging in metastatic breast cancer. J Clin Oncol (2004) 3.85
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res (2004) 3.63
CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol (2004) 3.38
Four-dimensional computed tomography: image formation and clinical protocol. Med Phys (2005) 2.78
Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med (2003) 2.76
The Lung Image Database Consortium (LIDC) and Image Database Resource Initiative (IDRI): a completed reference database of lung nodules on CT scans. Med Phys (2011) 2.48
"Crazy-paving" pattern at thin-section CT of the lungs: radiologic-pathologic overview. Radiographics (2003) 2.47
Primary thoracic sarcomas. Radiographics (2002) 2.46
Assessing respiration-induced tumor motion and internal target volume using four-dimensional computed tomography for radiotherapy of lung cancer. Int J Radiat Oncol Biol Phys (2007) 2.35
Breast lymphoma: imaging findings of 32 tumors in 27 patients. Radiology (2007) 2.31
[18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol (2005) 2.30
Frequent diagnostic errors in cardiac PET/CT due to misregistration of CT attenuation and emission PET images: a definitive analysis of causes, consequences, and corrections. J Nucl Med (2007) 2.29
Effect of respiratory gating on quantifying PET images of lung cancer. J Nucl Med (2002) 2.21
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg (2004) 2.18
Performance characteristics of a newly developed PET/CT scanner using NEMA standards in 2D and 3D modes. J Nucl Med (2004) 2.10
Focal FDG uptake in mediastinal brown fat mimicking malignancy: a potential pitfall resolved on PET/CT. AJR Am J Roentgenol (2004) 2.06
Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology (2008) 2.05
Evaluation of cardiac tumors with magnetic resonance imaging. Eur Radiol (2004) 2.01
Lung cancer screening. J Natl Compr Canc Netw (2012) 2.00
Incidental pulmonary emboli in oncology patients: prevalence, CT evaluation, and natural history. Radiology (2006) 1.93
Radiation pneumonitis: local dose versus [18F]-fluorodeoxyglucose uptake response in irradiated lung. Int J Radiat Oncol Biol Phys (2007) 1.89
Four-dimensional cone beam CT with adaptive gantry rotation and adaptive data sampling. Med Phys (2007) 1.84
Dynamic ventilation imaging from four-dimensional computed tomography. Phys Med Biol (2006) 1.80
Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2010) 1.79
Assessment of gross tumor volume regression and motion changes during radiotherapy for non-small-cell lung cancer as measured by four-dimensional computed tomography. Int J Radiat Oncol Biol Phys (2007) 1.74
A motion-incorporated reconstruction method for gated PET studies. Phys Med Biol (2006) 1.69
Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med (2006) 1.67
Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol (2009) 1.66
Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis. Radiographics (2004) 1.64
Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2012) 1.61
Lipoid pneumonia: spectrum of clinical and radiologic manifestations. AJR Am J Roentgenol (2010) 1.59
Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther (2009) 1.53
Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol (2009) 1.51
Low-dose CT reconstruction via edge-preserving total variation regularization. Phys Med Biol (2011) 1.50
Extended surgical staging for potentially resectable malignant pleural mesothelioma. Ann Thorac Surg (2005) 1.49
Teflon injection for vocal cord paralysis: false-positive finding on FDG PET-CT in a patient with non-small cell lung cancer. AJR Am J Roentgenol (2004) 1.44
Cardiac ¹⁸F-fluorodeoxyglucose uptake on positron emission tomography after thoracic stereotactic body radiation therapy. Radiother Oncol (2013) 1.44
The CT motion quantitation of lung lesions and its impact on PET-measured SUVs. J Nucl Med (2004) 1.44
Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol (2002) 1.41
Usefulness of imaging-guided catheter drainage and talc sclerotherapy in patients with metastatic gynecologic malignancies and symptomatic pleural effusions. AJR Am J Roentgenol (2002) 1.41
Incidental findings on integrated PET/CT that do not accumulate 18F-FDG. AJR Am J Roentgenol (2006) 1.40
Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment. Radiology (2012) 1.35
Imaging with 99mTc ECDG targeted at the multifunctional glucose transport system: feasibility study with rodents. Radiology (2003) 1.33
18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J Nucl Med (2009) 1.30
Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med (2009) 1.29
Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer. J Thorac Oncol (2008) 1.29
Anatomy of pericardial recesses on multidetector CT: implications for oncologic imaging. AJR Am J Roentgenol (2003) 1.27
Correlation between internal fiducial tumor motion and external marker motion for liver tumors imaged with 4D-CT. Int J Radiat Oncol Biol Phys (2007) 1.27
Thoracic complications of esophageal disorders. Radiographics (2002) 1.27
NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw (2007) 1.26
Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med (2002) 1.26
NCCN task force: clinical utility of PET in a variety of tumor types. J Natl Compr Canc Netw (2009) 1.24
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant (2010) 1.23
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood (2012) 1.19
Radiation injury of the lung after three-dimensional conformal radiation therapy. AJR Am J Roentgenol (2002) 1.18
PET/CT of esophageal cancer: its role in clinical management. Radiographics (2007) 1.15
Peritoneal carcinomatosis: role of (18)F-FDG PET. J Nucl Med (2003) 1.15
Update in the evaluation of the solitary pulmonary nodule. Radiographics (2014) 1.15
Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. J Nucl Med (2003) 1.14
NCCN Task Force Report: Bone Health In Cancer Care. J Natl Compr Canc Netw (2013) 1.12
Development of The American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America: recommendations of The American Association for Thoracic Surgery Task Force for Lung Cancer Screening and Surveillance. J Thorac Cardiovasc Surg (2012) 1.11
The value of 99mTc-sestamibi SPECT/CT over conventional SPECT in the evaluation of parathyroid adenomas or hyperplasia. J Nucl Med (2005) 1.11
Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach. J Exp Clin Cancer Res (2009) 1.10
Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome. Radiology (2005) 1.10
Incidental finding of focal FDG uptake in the bowel during PET/CT: CT features and correlation with histopathologic results. AJR Am J Roentgenol (2010) 1.09
4D-CT imaging with synchronized intravenous contrast injection to improve delineation of liver tumors for treatment planning. Radiother Oncol (2008) 1.08
Imaging taxane-induced tumor apoptosis using PEGylated, 111In-labeled annexin V. J Nucl Med (2004) 1.08
Computed tomography findings predicting invasiveness of thymoma. J Thorac Oncol (2011) 1.08
Radiation pneumonitis: correlation of toxicity with pulmonary metabolic radiation response. Int J Radiat Oncol Biol Phys (2008) 1.07
Imaging of non-small cell lung cancer of the superior sulcus: part 2: initial staging and assessment of resectability and therapeutic response. Radiographics (2008) 1.07
Sonography of pediatric small-bowel intussusception: differentiating surgical from nonsurgical cases. AJR Am J Roentgenol (2007) 1.07
Informed consent for imaging studies. AJR Am J Roentgenol (2013) 1.07
Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol (2012) 1.06